Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Mitsubishi Gas Chemical considers nucleic acid service business

by Aayushi Pratap
July 22, 2024 | A version of this story appeared in Volume 102, Issue 22

 

Mitsubishi Gas Chemical (MGC) has partnered with Hokkaido System Science, a Japanese biotech research service company, to explore entering the nucleic acid contract development and manufacturing organization (CDMO) business. While MGC’s main businesses are in making chemicals, it offers R&D services as well. MGC says the nucleic acid medicine market is set for growth, and it is aiming to add the segment to its existing antibody medicine CDMO business through its new partnership.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.